Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Impel NeuroPharma Closes $67.5 Million Series D to Advance CNS Portfolio

Seattle-based Impel NeuroPharma closed on a Series D financing totaling $67.5 million, co-led by KKR and Northwest Venture Partners.

Read More »

Impatient patients turn to online ‘buyers club’ for new drugs

Frustrated by delays in new medicines reaching their own country, a small but growing number of patients are turning to an online broker that bills itself as a legal version of the Dallas Buyers Club.

Read More »

Lilly migraine drug wins European panel thumbs-up

A European Medicines Agency panel recommended the approval of U.S. pharmaceutical group Eli Lilly’s migraine treatment, bringing the drug one step closer to being sold in the European Union.

Read More »

Amgen’s Aimovig Starts Strong, Multiple Myeloma Drug Wows at Conference

Amgen unveiled data at a multiple myeloma conference for AMG-420, which targets B-cell maturation antigen (BCMA).

Read More »

Novartis Halts Planned Price Increases For Drugs Amid Scrutiny of Relationship With Trump Attorney

Novartis is halting planned price increases on the Swiss pharma giant’s medications after President Donald Trump took Pfizer to task over price hikes, with Pfizer subsequently agreeing to roll back the company’s price increases.

Read More »

Amgen’s Aimovig halved migraine days in 30 percent of trial patients

A late-stage trial of Amgen Inc.’s Aimovig found that the experimental drug reduced episodic migraines by at least half in 30 percent of patients who had failed up to four previous treatments.

Read More »

Biohaven plunges as investors pit migraine data against Allergan’s drug

Biohaven Pharmaceutical Holding said the company’s treatment for acute migraine cleared two late-stage studies, but investors worried about its commercial viability as the efficacy data failed to distinguish from Allergan’s rival treatment.

Read More »

Lilly’s acute migraine drug succeeds in Phase III

Drugmaker Eli Lilly and Co. said its acute migraine drug lasmiditan succeeded in a key late-stage study, setting the stage for U.S. regulatory approval.

Read More »

Alder’s migraine drug data disappoints

Alder BioPharmaceuticals’ late-stage study data on its experimental treatment to prevent episodic migraine fell short of investors’ expectation.

Read More »

ZEMBRACE SymTouch now commercially available in the U.S.

Hyderabad, India and Princeton, NJ, USA. April 19, 2016 — Promius Pharma LLC, a subsidiary of Dr. Reddy’s Laboratories, announced today that ZEMBRACE SymTouch is now commercially available in the U.S. ZEMBRACE SymTouch is a prefilled, low-dose, ready-to-use, 2-step autoinjector containing 3 mg of sumatriptan, a selective 5-HT1B/ID receptor agonist. Because ZEMBRACE SymTouch is a […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2018 Focus: Top 50 Pharma, Company of the Year and more!

Subscribe

Ad Right Bottom